Describing Prostate Cancer Dynamics: Second Look at PSA- Doubling Time and PSA-Specific Growth Rate

Tisman, Glenn

doi:10.5772/53179

Cited by 2 publications

(2 citation statements)

References 79 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Furthermore, several retrospective clinical studies and even some meta-analyses have determined that PSA kinetics, including PSA response rate, nadir PSA level, TTN, or PSADT, predicted OS or disease progression [9,10,13,24]. PSADT predicting outcomes has been known for nearly 30 years, and it may closely indicate changes in prostate tumor volume, an independent predictor of biochemical relapse among patients that either underwent radical prostatectomy or endocrine treatment [28]. Doctor D'Amico et al demonstrated that patients with clinically localized prostate cancer treated with external beam radiation therapy with PSADT >12 months have lower risk of prostate cancer death within 5 years of relapse [29].…”

Section: Discussionmentioning

confidence: 99%

Prostate-Specific Antigen Kinetics Effects on Outcomes of Low-Volume Metastatic Prostate Cancer Patients Receiving Androgen Deprivation Therapy

Lin

Shao

et al. 2021

Journal of Oncology

View full text Add to dashboard Cite

Background. The present study aimed to analyse factors influencing the effects of androgen deprivation therapy (ADT) in patients with newly diagnosed metastatic castration-naïve prostate cancer (mCNPC), especially in low-volume disease (LVD), according to subclassification of metastatic prostate cancer established by the CHAARTED trial. Materials and Methods. We reviewed 648 patients with newly diagnosed mCNPC receiving ADT at Chang Gung Memorial Hospital from January 2007 to December 2016. Basic characteristics and PSA kinetics profile were subsequently evaluated. Results. 48.3% of LVD patients progressed to castration-resistant prostate cancer (mCRPC). Among them, CRPC group had significantly shorter time to PSA nadir (TTN) and faster time from PSA nadir to CRPC (TFNTC) ( p < 0.001) compared to non-CRPC group. PSA doubling time (PSADT) < 4 months tended to be associated with faster disease progression and shorter overall survival (OS). Among all patients with metastatic prostate cancer, those with shorter TTN <9 months, higher nadir PSA level ≥1 ng/mL, and shorter PSADT <3 months had increased tendency for biochemical progression. Conclusions. PSADT is an effective clinical predictor for disease progression and survival in LVD. Other PSA kinetics including TTN and TFNTC, though not the major predictors for disease progression or OS in LVD, might be the predictors for disease control status.

show abstract

Section: Discussionmentioning

confidence: 99%

Prostate-Specific Antigen Kinetics Effects on Outcomes of Low-Volume Metastatic Prostate Cancer Patients Receiving Androgen Deprivation Therapy

Lin

Shao

et al. 2021

Journal of Oncology

View full text Add to dashboard Cite

show abstract

“…We have previously shown that SGR is mathematically and biologically a more accurate measure for tumour growth rate than the widely used tumour volume doubling time [3,4]. Although the above equation is originally derived for tumour volume, it can also be used for tumour marker concentration levels for, e.g., prostate specific antigen, PSA [5], and CA125 [6]. Eq.…”

Section: Introductionmentioning

confidence: 99%

Estimation of tumour volume at therapy initiation by back-extrapolating the post-therapy regression curve of tumour volume

Mehrara

Forssell-Aronsson

2018

Appl Cancer Res

View full text Add to dashboard Cite

Background: Tumour volume at therapy initiation, V i , is rarely available in cancer patients, and the last pre-treatment tumour volume available is from previous diagnostic imaging (V d ). Therapeutic efficacy is thus evaluated by comparing tumour volume after treatment with V d , instead of V i , which results in underestimation of treatment efficacy. V i , together with V d , can also be used for estimation of the natural growth rate of tumour valuable for, e.g., screening programs, prognostication and individualised treatment planning such as chemotherapy scheduling. The aim of this work was to study the feasibility of estimating V i by back-extrapolating the post-therapy regression of tumour volume, based on data from animal model. Methods: Nude mice bearing human neuroendocrine GOT1 tumour cell line were treated with 177 Lu-DOTA-TATE. Tumour volumes were measured regularly after therapy and V i was estimated by back-extrapolation of (a) linear and (b) exponential regression lines of the two earliest post-therapy tumour volumes and (c) the long-term exponential regression of tumour volume. The estimated V i values (V est ) were compared with the measured volume of tumour at therapy initiation. Results: The linear regression of the two earliest post-therapy tumour volumes gave the best estimate for V i (V est = 0.91 V i , p < 0.00001), compared with the exponential regression models either on short-term (V est = 2.30 V i , p < 0.01), or long-term (V est = 0.93 V i , non-significant) follow up of tumour volume after therapy. Conclusion: Back-extrapolation of the early linear regression of tumour volume after therapy gave the best estimate for tumour volume at time of therapy initiation. This estimate can be used as baseline for treatment efficacy evaluation or for estimation of the natural growth rate of tumour (together with the measured tumour volume at pre-treatment diagnostic imaging).

show abstract

Describing Prostate Cancer Dynamics: Second Look at PSA- Doubling Time and PSA-Specific Growth Rate

Abstract: Though there is occasional homage paid to Gompertzian tumor growth, for practical purposes, when we care for patients, tumors are frequently undergoing exponential expansion.

Cited by 2 publications

References 79 publications

Prostate-Specific Antigen Kinetics Effects on Outcomes of Low-Volume Metastatic Prostate Cancer Patients Receiving Androgen Deprivation Therapy

Prostate-Specific Antigen Kinetics Effects on Outcomes of Low-Volume Metastatic Prostate Cancer Patients Receiving Androgen Deprivation Therapy

Estimation of tumour volume at therapy initiation by back-extrapolating the post-therapy regression curve of tumour volume

Contact Info

Product

Resources

About